Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2010)
27 slides from Nanosonics's shareholder meeting presentation, Nov 3, 2010
Slide 1: Annual General Meeting 3 November 2010
Nanosonics Limited (ASX:NAN) For personal use only Annual General Meeting 3 November 2010
Slide 2: Chairman's address: Maurie Stang
For personal use only Nanosonics Limited (ASX:NAN) Annual General Meeting Maurie Stang Non-Executive Chairman 3 November 2010
Slide 3: Nanosonics goal statement
Nanosonics For personal use only “At Nanosonics our goal is to safeguard the health and wellbeing of individuals, communities and environments by commercialising a stream of proprietary disinfection and sterilisation technologies”
Slide 4: The healthcare challenge
The healthcare challenge For personal use only „Killer‟ stomach bug strikes Australia The Australian, Wednesday 26 May 2010 Responsible for 8324 deaths in Britain in 2007 and in March this year killed 29 people in Copenhagen hospitals "SuperBug": NDM1 New Delhi Metallo-beta-lactamase ABC News, Thurs
Slide 5: Point of Care Disinfection Technologies - A Global Megatrend
Point of Care Disinfection Technologies- A Global Megatrend For personal use only • Aging population Minimally Drive rapid • Productivity turnaround of invasive • Patient throughput • Increased elective disinfection / surgeries procedures sterilisation • Enhanced patient • New technologies safety Po
Slide 6: Market Opportunity
Market Opportunity For personal use only Low temperature “point of care” solutions Marketcap Revenue Steris US$2.03b US1.3b Getinge US$5.0b US5.0b* Central Sterilising Services *Infection Control was 20% of group revenues Market Evolution
Slide 7: USA & Canada
USA & Canada For personal use only A market leader in Ultrasound in North America & Canada
Slide 8: For personal use only
For personal use only
Slide 9: Financials
Financials For personal use only Category Date Amount Total shares on issue @ 2 Nov 2010 226.6 million Share price @ 2 Nov 2010 A$ 0.87 Market capitalisation @ 2 Nov 2010 A$ 197.00 million Average daily trading @ 2 Nov 2010 360,000 volume(3mo) Cash on hand @ 30 Sept 2010 A$ 19.0 million Current Net
Slide 10: FY2010 Capital Raising
FY2010 Capital Raising For personal use only • AUD12.0m raised • SPP 3.6m raised • Capital Raising over subscribed Investment Status Additional manufacturing capacity Initial stage completed Expansion of technical resources Underway US Expansion Underway New Corporate Facilities Underway En
Slide 11: Identified Market Opportunities
Identified Market Opportunities For personal use only Current platform technologies can be leveraged into multiple future low temperature disinfection opportunities and discussions continue with a number of global partners. Opportunities include: • Food preparation • Transportation • Military • Prod
Slide 12: Key drivers of shareholder value
Key drivers of shareholder value For personal use only Financial • Business continues to de-risk with strong customer acceptance...iMED/Queensland Health/GEHC • Sustainable high margins on Trophon EPR & dedicated NanoNebulant Pipeline • Multiple growth opportunities identified & under assessment • $
Slide 13: CEO address: David Radford
For personal use only Nanosonics Limited (ASX:NAN) Annual General Meeting David Radford Director and CEO 3 November 2010
Slide 14: Nanosonics' Key Milestones 2010
Nanosonics’ Key Milestones 2010 For personal use only • Exclusive agreement with GE Healthcare to distribute Trophon EPR in US/Canada • FDA application on track • Accelerated development of upgraded Trophon for international release • Establishment of infrastructure to support EU & Global roll-out •
Slide 15: Trophon EPR Competitive advantage
Trophon EPR Competitive advantage For personal use only The only point of care, low temperature, automated ultrasound reprocessor available globally Customer benefits: – New standard in high level disinfection – Short operating time • Process time only 7 minutes • Improve workflow more patients –
Slide 16: Regulatory Process - Major Markets
Regulatory Process-Major Markets For personal use only FEB 11 US Dec 10 FDA Approval Japan (pending FDA) MOH Submission DEC 08 TGA Approval NOV 08 New Zealand Product registration / SEPT 08 approval to market Canada CMDCAS approval MAY 08 Europe CE Mark Obtained
Slide 17: Globalising the Trophon EPR: Australia & New Zealand
Globalising the Trophon EPR For personal use only Australia & New Zealand • Product launched • Total Nanosonics market opportunity ~ $25M • Strong regulatory support • Good customer acceptance - iMED/Queensland Health/District Health Boards-Auckland “The Trophon EPR will make the task of disinfectin
Slide 18: Globalising the Trophon EPR: Europe
Globalising the Trophon EPR For personal use only Europe • Nanosonics’ market opportunity $280M France • Initial product release • National move banning the use of glutaraldehydes • Positive market feedback Germany & UK • Targeted release to Key Opinion Leaders mid FY2011 “It is a well-known problem
Slide 19: US & Canada Opportunity
US & Canada Opportunity For personal use only • Market Opportunity >100k Trophon Units • >200m Ultrasound Procedures • GE Healthcare-Market Leader in Ultrasound Sales-US/Canada • Bundling opportunity for Trophon with the leading Women’s imaging ultrasound system • Opinion leader able to drive new st
Slide 20: US Update
US Update For personal use only • FDA mandate use of High Level Disinfection between patients supported by Centre for Disease Control/American College of Radiologists • Updated MoU executed with GEHC • GE agreement (USA/International) on track for execution in CY2010 • FDA 510(k) application on trac
Slide 21: Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008
Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 For personal use only • A vaginal probe and all endocavitary probes require routine probe disinfection between examinations • Glutaraldehyde may shorten the life of the transducer and might have toxic effects on the gametes
Slide 22: Trophon Development
Trophon Development For personal use only • Early component QA issues & controlled roll out successfully managed • Clearly defined roadmap in both North America & globally with GE as a partner • Significant shift in short term priorities to focus on the GE Ultrasound HLD partnership • Significant in
Slide 23: Production Roadmap 2011
Production Roadmap 2011 For personal use only Production Expansion • Additional production capacity contracted (ISO accredited manufacturing in Sydney) • Optimised sub assembly production enhancing production efficiencies • Scaling of enhanced Trophon EPR for global release • Planned new premises 2H
Slide 24: For personal use only
For personal use only
Slide 25: Product development
Product development For personal use only Nanosonics‟ platform technologies are transferable and highly scalable to other applications
Slide 26: Summary
Summary For personal use only • Significant commercial validation in ANZ driven by strong customer acceptance of the technology of the Trophon EPR • GEHC on track for appointment as master distributor of Trophon EPR in US/Canada • FDA application on track • Focus upon scalable manufacturing of enhan
Slide 27: For personal use only
For personal use only